Answers are grounded in this paper and cite their sources.
Background Diabetic retinopathy (DR) remains a major microvascular complication of type 2 diabetes, yet risk assessment in routine practice is largely centered on glycemic exposure and disease duration. The Naples Prognostic Score (NPS) integrates nutritional and inflammatory indicators, including serum albumin, total cholesterol, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio. Its relation to incident DR has not been established. Methods This retrospective cohort study included 468 adults with type 2 diabetes who were free of DR at baseline and underwent longitudinal retinal assessment at a tertiary care center. NPS was categorized from 0 to 4 using prespecified component cutoffs. Cox proportional-hazards models estimated associations of NPS with incident DR. The fully adjusted model included demographic characteristics, diabetes duration, lifestyle factors, metabolic and renal indices, and use of insulin and statins. Kaplan–Meier analysis, restricted cubic splines, subgroup analyses, and an analysis excluding events within 12 months assessed the consistency of the findings. Results Over 1,440.4 person-years of follow-up, 156 participants (33.3%) developed DR. The median follow-up was 35.4 months. Incident DR was more frequent among participants with a higher NPS. In the fully adjusted model, each one-point increase in NPS was associated with a 53.6% higher hazard of DR (hazard ratio [HR] 1.54, 95% confidence interval [CI] 1.30–1.82; p < 0.001). Compared with NPS 0, adjusted HRs were 1.94 (95% CI 0.91–4.15), 1.88 (0.89–3.99), 4.08 (1.89–8.78), and 7.16 (2.88–17.76) for NPS 1 through 4, respectively (P for trend <0.001). The association was directionally consistent across prespecified subgroups and remained evident after exclusion of early events (HR 1.51, 95% CI 1.23–1.85). Conclusion A higher baseline NPS was independently associated with incident DR in this retrospective cohort. NPS may complement, rather than replace, established clinical risk assessment. Confirmation in prospective multicenter cohorts is required before use in clinical decision-making.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: